modelCinnarizine
Extends from Pharmacolibrary.Drugs.ATC.N.N07CA02.
Information
| name: | Cinnarizine | |
| ATC code: | N07CA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 75 | mg |
| volume of distribution: | 83 | L |
| clearance: | 47 | L/h |
| other parameters in model implementation | ||
Cinnarizine is a piperazine derivative antihistamine commonly used to treat and prevent motion sickness, vertigo, and balance disorders. It acts as a selective calcium channel blocker and histamine H1 receptor antagonist. Although widely used in many countries, cinnarizine is not approved for use in the United States or some other regions.
Pharmacokinetics
Reported pharmacokinetic parameters in healthy adult volunteers after a single oral dose administration.
References
Paton, DM, & Webster, DR (1985). Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clinical pharmacokinetics 10(6) 477–497. DOI:10.2165/00003088-198510060-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2866055
Ramirez, G, et al., & Boyd, BJ (2021). Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. Drug delivery and translational research 11(3) 1236–1244. DOI:10.1007/s13346-020-00851-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/32935235
Yan, M, et al., & Zhu, YG (2010). Quantitative determination of pimozide in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study. Journal of pharmaceutical and biomedical analysis 51(5) 1161–1164. DOI:10.1016/j.jpba.2009.11.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19969437
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)